Incyte Clinical Trials Results

April 20, 2023 – Incyte published a press release on European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents.

May 17, 2021 – Incyte published a press release on the success of their Phase 3 Clinical Trial for ruxolitinib.

Incyte is a past and present sponsor of GVF. This is an unpaid post.

About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development, and commercialization of proprietary therapeutics. For additional information on Incyte, please visit and follow @Incyte.